ClinicalTrials.gg
CompletedNCT05069610Updated Dec 22, 2023

Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19

A Phase 1/2 interventional study of AD17002 and Placebo (Formulation buffer) in COVID-19, sponsored by Advagene Biopharma Co. Ltd.. Completed at 2 sites in Taiwan. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-22.

Sponsored by Advagene Biopharma Co. Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in COVID-19 with a site in Taiwan — 12 open to participants now, 13 under way, 7 of them phase 3. COVID-19 · Taiwan.

Enrollment
50th of 56
30 · median 137
Started
2022
with 21 others
Phase 1/2
3 of 78
none open now
Registered
26th of 78
by date

Among the 78 studies in COVID-19 with a site in Taiwan, this one is the 50th largest by enrollment of the 56 interventional ones that give a count, is one of 22 that started in 2022, is one of 3 in phase 1/2, and was the 26th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

12 of the 78 studies in COVID-19 with a site in Taiwan are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in COVID-19 with a site in Taiwan, or all of them as a file.
02

Study summary

AD17002 has demonstrated superior safety and efficacy as a nasal adjuvant function to an influenza vaccine in two completed clinical studies, and has innate immune modulatory and anti-inflammatory properties which could potentially be an effective treatment for SARS-CoV-2 infection.

This Phase 2a, multi-center study is set up to assess the safety, tolerability, and potential efficacy of AD17002 in participants with mild to moderate COVID-19. The Immunogenicity of repeated doses of AD17002 will also be explored.

Read the detailed description

AD17002 has demonstrated superior safety and efficacy as a nasal adjuvant function to an influenza vaccine in two completed clinical studies and has innate immune-modulatory and anti-inflammatory properties which could potentially be an effective treatment for SARS-CoV-2 infection.

This Phase 2a, multi-center study is set up to assess the safety, tolerability, and potential efficacy of AD17002 in participants with mild to moderate COVID-19. The cycle threshold (Ct) was used as a surrogate biomarker for viral clearance in the exploratory study.

The COVID-19 pandemic has led to significant mortality in global populations and suppression of the economy. The prompt development of the vaccine for SARS-CoV-2 represents an unprecedented achievement for mankind, nevertheless, the unstoppable transmission of the virus highlights human's insufficient and lack of preparedness in mucosal immunity, which acts as the port of entries to not just SARS-CoV-2, but many viruses.

The AD17002, also known as LTh(αK), is an immunomodulator, which induces expression of type I and III interferons (IFN-I/III) from mucosal epithelial cells. The IFN-I/III are critical components to innate immunity, the first line defender against infection, and modulator and initiator of adaptive immunity. The IFN-I is antagonized by many SARS-CoV-2 viral proteins and studies have shown the association between IFN-I deficiency and severe COVID-19. In this study, we intended to treat subjects with AD17002, which induced nasal epithelial cells to express IFN-I/III.

Participants who meet the eligibility criteria will be isolated and confined to the study site to receive treatment for COVID-19. Eligible participants will be assigned to 2 cohorts, Cohort 1 and Cohort 2, sequentially. Cohort 1 will receive 3 doses of AD17002 or placebo weekly, while Cohort 2 will receive 3 doses of LTh(αK) or placebo every other day (Days 1, 3, and 5). Within each cohort, participants will be randomized in a 2:1 ratio to receive standard-of-care treatment and add-on therapy of AD17002 at 20 μg or placebo. Randomized participants will be assigned a participant number. The participants, site personnel, and the Sponsor will be blinded to the treatment assignment. Randomization will not be stratified and participants who withdraw from the study after starting treatment will not be replaced, except for participants who undergo sentinel dosing in Cohort 2.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • SARS-CoV-2
  • COVID-19
  • Therapy, viral clearance, immunomodulator, IFN, innate
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 20 and ≤ 70 years
  2. SARS-CoV-2 infection confirmed by real-time RT-PCR ≤ 4 days before randomization.
  3. Symptoms of mild to moderate illness with COVID-19 at Screening. At least one key COVID-19 symptom should have a score of 2 or higher using the scoring system in the diary card, with the exception of fever, sense of smell, and sense of taste where participants may be enrolled with a score of 1 or higher.
  4. Have a negative serum pregnancy test at Screening (for female participants of ). A female participant who is of childbearing potential agrees to remain abstinent or use (or have their partner use) two acceptable methods of within the projected duration of the study. Acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines.
  5. (ALT) or aspartate aminotransferase (AST) ≤ 2.5-fold of (ULN) and total ≤ 1.5-fold of ULN.
  6. ≥ 50 mL/min.
  7. A female participant who is not of childbearing potential is eligible without requiring the use of contraception. A female participant who is not of childbearing potential is defined as one who has either:

    1. Reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the range as determined by the laboratory, or 12 months of spontaneous amenorrhea), or
    2. At least six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or
    3. Bilateral tubal ligation
  8. Participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written .
  9. Provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

Exclusion criteria

Exclusion Criteria:

  1. Participant has clinical signs suggestive of moderate (pneumonia) or more severe illnesses with COVID-19 (as defined in the Taiwan CDC "Interim Guideline for Clinical Management of SARS-CoV-2 Infection Version 13" (Taiwan CDC, Clinical Management of SARS-CoV-2 Infection).
  2. Participation in any other clinical study of an agent treatment for SARS- CoV-2 infection within 30 days prior to the first IMP dosing.
  3. Participant who has a history of confirmed SARS-CoV-2 infection.
  4. Concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2 \< 24 hours prior to the first IMP dosing.
  5. History of severe renal disease (treatment with dialysis or phosphate binders) or clinically apparent hepatic impairment (e.g., jaundice, cholestasis, hepatic synthetic impairment, active hepatitis).
  6. Impaired cardiac function or cardiac diseases as judged by the Investigator.
  7. History of anaphylaxis reaction to any known or unknown cause.
  8. persons as result of illness (e.g., infection) or treatment.
  9. Documented history of Bell's palsy.
  10. History of allergic reaction to kanamycin.
  11. Immunosuppressive treatment within 3 months prior to the Screening Visit.
  12. Ongoing treatment with any specific immunotherapy at the time of the Screening Visit.
  13. Assessed by the Investigator to be ineligible to participate in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Standard of care + AD17002 (3 weekly doses)

    Received 3 weekly doses of AD17002 20 μg/dose of AD17002 by intranasal route

    Biological: AD17002

  • Placebo comparator
    Standard of care + Placebo (3 weekly doses)

    Received 3 weekly doses of Placebo Formulation buffer by the intranasal route

    Biological: Placebo (Formulation buffer)

  • Experimental
    Standard of care + AD17002 (3 doses in 5 days)

    Received 3 doses of AD17002 in 5 days 20 μg/dose of AD17002 by the intranasal route on days 1, 3, and 5

    Biological: AD17002

  • Placebo comparator
    Standard of care + Placebo (3 doses in 5 days)

    Received 3 doses of Placebo in 5 days Formulation buffer by the ntranasal route on days 1, 3, and 5

    Biological: Placebo (Formulation buffer)

Interventions

  • BiologicalAD17002

    A recombinant protein

  • BiologicalPlacebo (Formulation buffer)

    Formulation buffer

06

What researchers measure

Primary outcomes

  1. The proportion of participants who experience adverse events

    Clinicians and Patients reported AEs in the study period (7 weeks)

    Time frame: 7 weeks

  2. The proportion of participants with treatment-emergent adverse events (TEAE) leading to investigational medicinal products (IMPs) discontinuation

    Measuring and recording the AEs caused by treatment.

    Time frame: 7 weeks

  3. The nasal tolerability to investigational medicinal products (IMPs)

    Nasal symptoms will be assessed by participants and ear-nose-throat (ENT) specialists on symptoms include runny nose, stuffy nose, nasal discomfort, sneezing, lacrimation, change in vision, red eyes, facial swelling, nasal pain. Symptom Score Guide: 0= None; 1= Mild; 2= Moderately; 3= Severe

    Time frame: 7 weeks

Secondary outcomes

  1. The time to proportions of participants have a Ct≥30

    Measuring the RT-PCR on RdRp and E gene

    Time frame: 7 weeks

  2. Time to recovery* of fever (days)

    Fever is defined as temperatures of ≥ 36.6°C (axilla), or ≥ 37.2°C (oral), or ≥ 37.8°C (rectal or tympanic) over a 48-hour period. Recovery of fever is defined as occurring when body temperature is \< 36.6°C (axilla), or \< 37.2°C (oral), or \< 37.8°C (rectal or tympanic) over a 48-hour period.

    Time frame: 7 weeks

  3. Time to recovery* of sore throat (days)

    Recovery of sore throat is defined as occurring when the symptom of sore throat has resolved to a score of 0 over a 48 hour period

    Time frame: 7 weeks

  4. Time to recovery* of cough (days

    Recovery of cough is defined as occurring when the symptom of cough has resolved to a score of 0 over a 48 hour period

    Time frame: 7 weeks

  5. Time to recovery* of fatigue (days).

    Recovery of fatigue is defined as occurring when the symptom of fatigue has resolved to a score of 0 over a 48 hour period

    Time frame: 7 weeks

  6. Time to recovery* of muscle/body pain (days)

    Recovery of muscle/body pain is defined as occurring when the symptom of muscle/body pain has resolved to a score of 0 over a 48 hour period

    Time frame: 7 weeks

  7. Time to recovery* of other symptoms (days)

    Recovery of symptom is defined as occurring when the symptom has resolved to a score of 0 over a 48 hour period

    Time frame: 7 weeks

  8. The mean change from baseline to each specified time point on National Early Warning Score 2 (NEWS2)

    Clinicians or study staffs report the NEWS 2 scores for each subject.

    Time frame: 7 weeks

Other outcomes

  1. Changes to anti-SARS CoV-2 antibody titers from baseline

    Measuring virus-specific IgG within serum

    Time frame: 7 weeks

  2. Changes to pre-specified immunological markers

    Measuring the IL6, lymphocyte count and neutrophil-to-lymphocyte ratio.

    Time frame: 7 weeks

  3. Viral genome integrity analysis

    Measuring the ratio of different viral gene expressed after treatments

    Time frame: Cohort 1, 3 weeks; Coohort 2, 8 days

07

Study locations

2 sites
  • Advagene Biopharma
    Taipei, 104, Taiwan
  • Chang Gun Medical Foundation
    Taoyuan, 333423, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Oct 2023, 19 months.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 19 months is above that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2021
First posted
Oct 6, 2021
StartActual
Mar 21, 2022
Primary completionActual
Oct 31, 2023
CompletionActual
Dec 18, 2023
Last update
Dec 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05069610
Lead sponsor
Advagene Biopharma Co. Ltd.
Responsible party
Sponsor
First posted
Oct 6, 2021
Start date
Mar 21, 2022
Primary completion
Oct 31, 2023
Completion
Dec 18, 2023
Last update
Dec 22, 2023

Study contacts

Mingi Chang, PhD
study director · Advagene Biopharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heat-labile enterotoxin, E coli

Start the discussion